← board
STTK
Shattuck Labs, Inc.distress 6/10 · elevated risk$6.83-3%today-13% from 52w high
Oncology 2
Lead: inflammatory bowel disease · est. market ~$20B (approx, global)
Revenue
pre-revenue
Liquidity
$90M
Runway
2.2 yrs
Shares 1y
+60%
Price & events
+56.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.8%
1D
-3.5%
1W
+26.6%
1M
-10.8%
3M
+64.5%
6M
+732.3%
1Y
+52.0%
2Y
-69.4%
5Y
-84.9%
All
Overview
- Market Cap
- $523.34M
- Volume
- 21.21K
- 52 Week Range
- $0.73 – $7.88
- Total Shares
- 76.68M
- Float Shares
- 48.51M
- Short %
- 6.44%
- % Held by Insiders
- 4.53%
- % Held by Institutions
- 59.56%
- RVOL
- 0.01x
- Beta
- 1.06
Pipeline stages · 3 programs
SL-325
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pegylated Liposomal Doxorubicin, SL-172154, Mirvetuximab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
SL-172154, Azacitidine (AZA), Venetoclax
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-07 | Phase 1 | SL-325 | Healthy Volunteers | 72 | active not recruiting |
| 2025-02-07 | Phase 1 | Pegylated Liposomal Doxorubicin, SL-172154, Mirvetuximab | Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal Carcinoma | 86 | completed |
| 2025-02-06 | Phase 1 | SL-172154, Azacitidine (AZA), Venetoclax | Acute Myeloid Leukemia, Myelodysplastic Syndromes | 106 | terminated |
Catalyst news & presentations · 7
- first half of 2027Guided 55%regulatory submissionFiled (NDA/BLA)SL-846 · IND filing for SL-846 (DR3xIL-23R bispecific).SEC 8-K
- third quarter of 2026Guided 70%trial initiationsecondaryPhase 2SL-325 · Initiation of RECEPTIVE-CD1 Phase 2b trial of SL-325 in Crohn's disease.SEC 8-K
- 2026-08-14earningsEarningsEarnings releaseyahoo
- this quartertrial initiationsecondaryPhase 1SL-325 · Phase 1 trial initiation for SL-325 in inflammatory bowel diseaseSEC 8-K
- Q3 2025regulatory submissionFiled (NDA/BLA)SL-325 · IND filing for SL-325 expected in Q3 2025SEC 8-K
- 2024-10-01trial discontinuedSL-172154 · Discontinued clinical development of SL-172154SEC 8-K
- 2024-09-30withdrawalMutual termination of collaboration agreement with Ono PharmaceuticalSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $15 (+117% upside) · 6 analysts
- 2026-07-20Leerink PartnersOutperform
- 2026-06-09CitigroupBuy
- 2026-06-08NeedhamBuy
- 2026-06-08HC Wainwright & Co.Buy
- 2026-06-05CitigroupNeutral → Buy
- 2026-05-08WedbushOutperform
Competitors — inflammatory bowel disease
Recent news
- 2026-07-20Shattuck Labs Inc. (STTK) Drops Sharply as Biotech Sector Faces Headwinds - Iron Condor Alert - dars.gov.et
- 2026-07-20STTK Initiated Coverage by Leerink Partners -- Rating Set to Out - GuruFocus
- 2026-07-20STTK Initiated Coverage by Leerink Partners -- Rating Set to Out - GuruFocus
- 2026-07-19STTK stock trades steady as Shattuck Labs highlights cash position and clinical progress - Ad-hoc-news.de
- 2026-07-18Redmile updates 9.9% Shattuck Labs (STTK) stake after July trades - Stock Titan
- 2026-07-08Shattuck Labs, Inc. (STTK) Discusses Phase I Results for DR3 Blocking Antibody SL-325 and Pipeline Update - Slideshow (NASDAQ:STTK) 2026-07-08 - Seeking Alpha
- 2026-07-07Shattuck Labs (STTK) CTO exercises options and makes small 10b5-1 sale - Stock Titan
- 2026-07-07Shattuck Labs CTO Abhinav Shukla sells $2,874 in company stock - Investing.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.